Abstract:There are no vaccines licensed for enterotoxigenic Escherichia coli (ETEC), a leading cause of diarrhea for children in developing countries and international travelers. Virulence heterogeneity among strains and difficulties identifying safe antigens for protective antibodies against STa, a potent but poorly immunogenic heat-stable toxin which plays a key role in ETEC diarrhea, are challenges in ETEC vaccine development. To overcome these challenges, we applied a toxoid fusion strategy and a novel epitope- and structure-based multiepitope fusion antigen (MEFA) vaccinology platform to construct two chimeric multivalent proteins, toxoid fusion 3xSTaN(12S)-mnLT(R192G/L211A) and adhesin CFA/I/II/IV MEFA, and demonstrated that the proteins induced protective antibodies against STa and heat-labile toxin (LT) produced by all ETEC strains or the seven most important ETEC adhesins (CFA/I and CS1 to CS6) expressed by the ETEC strains causing 60 to 70% of diarrheal cases and moderate to severe cases. Combining two proteins, we prepared a protein-based multivalent ETEC vaccine, MecVax. MecVax was broadly immunogenic; mice and pigs intramuscularly immunized with MecVax developed no apparent adverse effects but had robust antibody responses to the target toxins and adhesins. Importantly, MecVax-induced antibodies were broadly protective, demonstrated by significant adherence inhibition against E. coli bacteria producing any of the seven adhesins and neutralization of STa and cholera toxin (CT) enterotoxicity. Moreover, MecVax protected against watery diarrhea and provided over 70% and 90% protection against any diarrhea from an STa-positive or an LT-positive ETEC strain in a pig challenge model. These results indicated that MecVax induces broadly protective antibodies and prevents diarrhea preclinically, signifying that MecVax is potentially an effective injectable vaccine for ETEC. IMPORTANCE Enterotoxigenic Escherichia coli (ETEC) bacteria are a top cause of children's diarrhea and travelers' diarrhea and are responsible for over 220 million diarrheal cases and more than 100,000 deaths annually. A safe and effective ETEC vaccine can significantly improve public health, particularly in developing countries. Data from this preclinical study showed that MecVax induces broadly protective antiadhesin and antitoxin antibodies, becoming the first ETEC vaccine candidate to induce protective antibodies inhibiting adherence of the seven most important ETEC adhesins and neutralizing the enterotoxicity of not only LT but also STa toxin. More importantly, MecVax is shown to protect against clinical diarrhea from STa-positive or LT-positive ETEC infection in a pig challenge model, recording protection from antibodies induced by the protein-based, injectable, subunit vaccine MecVax against ETEC diarrhea and perhaps the possibility of intramuscularly administered protein vaccines for protection against intestinal mucosal infection.

E. coli Vaccine Development

The Inactivated Vaccine Immunization Experiment of E. coli

Development of the Multivalent Prolis-Adjuvant Inactivated Vaccine Against Chicken E. coli Disease

Progress and Hurdles in the Development of Vaccines Against Enterotoxigenicescherichia Coliin Humans

Development of a new candidate vaccine against piglet diarrhea caused by Escherichia coli

Production of a new tetravalent vaccine targeting fimbriae and enterotoxin of enterotoxigenic Escherichia coli

Generation of an Inactivated Vaccine for Avian Pathogenic Escherichia Coli Using Microarrays: A More Rational Approach to Inactivated Vaccine Design

Safety,Stability and Lmmunogenicity of DNA Vaccine with Attenuated Salmonella Typhimurium As the Oral Delivery Vector

Current Progress in Developing Subunit Vaccines Against Enterotoxigenic Escherichia Coli-Associated Diarrhea

Eimeria tenella: ginsenosides-enhanced immune response to the immunization with recombinant 5401 antigen in chickens.

Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate

Towards an Attenuated Enterohemorrhagic Escherichia Coli O157:H7 Vaccine Characterized by a Deleted Ler Gene and Containing Apathogenic Shiga Toxins

Construction and characterization of EHEC 0157△ler/stx(pBR322::stx 1/2B::eae)

Protective Efficacy of a Novel Multivalent Vaccine in the Prevention of Diarrhea Induced by Enterotoxigenic Escherichia Coli in a Murine Model

A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice

Application of Recombinant Lactic Acid Bacteria (LAB) Live Vector Oral Vaccine in the Prevention of F4+ Enterotoxigenic Escherichia coli

Development of a Vaccine Against Experimental Cholera and Escherichia coli Diarrheal Disease

Development of a chitosan‐modified PLGA nanoparticle vaccine for protection against Escherichia coli K1 caused meningitis in mice

Development of an O-polysaccharide Based Recombinant Glycoconjugate Vaccine in Engineered E. Coli Against ExPEC O1.

Preparation and Application of Avian Escherichia Coli Fusion Strain Expressing Two Different Omp Patterns

Fusion Expression and Immunogenicity of EHEC EspA-Stx2Al Protein: Implications for the Vaccine Development